Connect with us


Finerenone reduces risk for new-onset AF in diabetic kidney disease – Healio

Treatment with the mineralocorticoid receptor antagonist finerenone reduced the risk for new-onset AF or flutter by 29% compared with placebo in adults with diabetic…



Source: Filippatos G, et al. Late Breaking Clinical Trials V. Presented at: American College of Cardiology Scientific Session; May 15-17, 2021 (virtual meeting).
Bayer AG funded FIDELIO-DKD and analyses were conducted by the sponsor. Filippatos reports he received lectures fees or is a committee member of trials and registries sponsored by Amgen, Bayer, Boehringer Ingelheim, Medtronic, Novartis, Servier and Vifor Pharma. He is a senior consulting editor for JACC:…

Click here to view the original article.

Continue Reading

You might also like ...

Article feature image
Dr Zac Turner reveals why women live longer than men –
Article feature image
California launches digital Covid vax portal –